小于等于2 cm非小细胞肺癌淋巴结切除因素分析

Analysis of Factors Affecting Lymph Node Resection in Non-Small Cell Lung Cancer with Tumor Size ≤ 2 cm

摘要: 非小细胞肺癌(NSCLC)是一种常见的恶性肿瘤，其预后与肿瘤的大小、分期、位置以及患者的个体差异等多种因素相关。在NSCLC患者中，那些具有小于或等于2 cm肿瘤的早期患者，通常具有较好的生存预后。然而，对于这部分患者的治疗策略，特别是是否进行淋巴结切除以及切除的程度，一直存在争议。本文综述了小于等于2 cm的NSCLC患者中，进行淋巴结切除的相关因素及其对患者预后的影响。通过回顾近年来的相关研究，发现决定是否进行淋巴结切除的因素包括肿瘤的具体位置、病理分型、分子遗传特征、术前淋巴结状态的评估、患者的全身状况和术后恢复预期等。研究表明，即使是在直径小于等于2 cm的NSCLC患者中，肿瘤的微观侵袭性、淋巴管内侵犯以及肿瘤的分子生物学特征等因素可能提示着潜在的淋巴结转移风险，进而影响着是否要进行更广泛的淋巴结切除。此外，多组学分析和液体活检等新兴技术在淋巴结转移确诊和风险评估中，也开始发挥着重要作用。而在术前评估中，影像学检查如胸部CT、PET-CT等对淋巴结转移的评估准确性高，对于指导手术计划和范围具有重要价值。术中的冰冻切片检查也为即时决定淋巴结切除范围提供了依据。从治疗效果来看，适度淋巴结清扫对于确保根治性切除以及提供更准确的分期具有关键作用，同时也有研究指出，过度的淋巴结清扫可能会增加患者的术后并发症风险，并不一定带来生存上的益处。综上，针对小于等于2 cm的NSCLC患者进行淋巴结切除时，需要综合考虑多种因素，制定合理的治疗策略，从而在保证治疗效果的同时，最大程度地减少患者的治疗负担。

Abstract: Non-small cell lung cancer (NSCLC) is a common malignant tumor, and its prognosis is related to multiple factors including the size of the tumor, staging, location, and the individual differences of patients. Early-stage NSCLC patients with tumors measuring 2 cm or smaller generally have a better survival prognosis. However, there is ongoing controversy regarding the treatment strategy for these patients, particularly concerning whether lymph node dissection is necessary and to what extent it should be performed. This article reviews factors related to lymph node dissection and its impact on the prognosis of NSCLC patients with tumors measuring up to 2 cm. Recent studies suggest the decision to perform lymph node dissection includes factors such as the precise location of the tumor, histological type, molecular genetic characteristics, preoperative assessment of lymph node status, the patient’s general health, and expectations for postoperative recovery. Research indicates that even in NSCLC patients with tumor diameters of 2 cm or less, elements such as microscopic invasiveness, lymphovascular invasion, and the molecular-biological characteristics of the tumor may indicate potential risks for lymph node metastasis, thereby influencing the need for more extensive lymph node dissection. Furthermore, emerging techniques such as multi-omics analyses and liquid biopsies are playing an important role in the diagnosis and risk assessment of lymph node metastasis. In preoperative assessment, imaging studies such as thoracic CT and PET-CT have a high accuracy for evaluating lymph node metastasis and are valuable for guiding surgical plans and scopes. Intraoperative frozen section examinations also provide the basis for immediate decisions about the extent of lymph node dissection. From a treatment outcome perspective, moderate lymph node dissection is crucial for ensuring radical resection and providing more accurate staging. However, some studies have noted that excessive lymph node dissection may increase the risk of postoperative complications without necessarily improving survival. In conclusion, when considering lymph node dissection for NSCLC patients with tumors measuring up to 2 cm, a variety of factors need to be combined to develop a reasonable treatment strategy that ensures therapeutic effectiveness while minimizing the treatment burden on patients.